Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | MET | P08581 | 4/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339773 | 0.94 | BRAF (0.41) | BRAFKDRMETAXLFLT4 | |
| SCHEMBL12336459 | 0.89 | BRAF (0.45) | BRAFKDRAXLMAPK14TNNI3K | |
| SCHEMBL12336447 | 0.82 | BRAF (0.44) | BRAFSYKKDRMETAXL | |
| SCHEMBL12336399 | 0.82 | BRAF (0.48) | BRAFKDRMAPK14TNNI3K | |
| SCHEMBL12336578 | 0.81 | BRAF (0.46) | BRAFKDRMAPK14TNNI3K | |
| SCHEMBL12336249 | 0.81 | GSK3A (0.49) | BRAFSYKKDRMETAXL | |
| SCHEMBL14949385 | 0.79 | SYK (0.41) | SYKKDRMETAXLFLT4 | |
| SCHEMBL12336445 | 0.79 | BRAF (0.46) | BRAFKDRAXLMAPK14TNNI3K | |
| SCHEMBL14949313 | 0.78 | KDR (0.46) | KDRMETTEK | |
| SCHEMBL12336457 | 0.78 | BRAF (0.43) | BRAFKDRMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | BRAF 39/4885SYK 637/4885KDR 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.